Cefazolin interactions

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Ertapenem label, Contraindications)

Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. (Imipenem and cilastatin label, Warnings and precautions)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Cefazolin label, Contraindications)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (Cefazolin label, Drug interactions)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (Cefazolin label, Drug interactions)

Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (Rifampin label, Warnings)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Ethacrynic acid label, Drug interactions)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. (Furosemide label, Drug interactions)

Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. (Gentamicin label, Drug interactions)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (Mycophenolate label, Drug interactions)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (Cefazolin label, Warnings and precautions)

Drug Interactions Protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins (see DOSAGE AND ADMINISTRATION ). (Protamine label, Precautions)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (Cefazolin label, Warnings and precautions)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Cefazolin label, Warnings and precautions)

Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. (Aminophylline label, Drug interactions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Before initiating therapy with Meropenem for injection, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. (Meropenem label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Some drugs (e.g. cefazolin, cephalothin), however, may interfere with certain HPLC techniques. (Theophylline label, Drug interactions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Cefazolin label, Warnings and precautions)